Novartis Pharmaceuticals Corporation

Part of Novartis

CompanySwitzerlandFounded 1996

ROR

Novartis Pharmaceuticals Corporation develops 69 assets, the furthest approved (Afinitor in advanced breast cancer). Mostly small molecule and antibody acting on PIK3CA, IL17A and PIK3CD; based in Switzerland, founded in 1996.

69
Assets
Furthest stage
Approved
1,361
Trials
275
Signals

Pipeline

69
  • Afinitor

    Approved, Small molecule, FKBP1A, advanced breast cancer, breast neoplasm

  • Aliskiren/Amlodipine

    Fixed-dose combination of renin inhibitor aliskiren and calcium channel blocker amlodipine.

    Approved, not sold in the US, Small molecule, hypertension (Phase 3), cardiovascular events (Phase 3)

  • Aliskiren/valsartan

    Combination of direct renin inhibitor and angiotensin II type 1 receptor antagonist reducing blood pressure.

    Approved, not sold in the US, Small molecule, hypertension (Phase 3), stage 2 hypertension (Phase 3)

66 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms9
  • Trials1,675
  • Deals1
  • Signals20
  • Integrity notices1
  • Similar companies6

Papers

Intelligence